110 related articles for article (PubMed ID: 19724878)
21. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
22. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
23. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.
Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
Mol Biotechnol; 2021 Dec; 63(12):1192-1222. PubMed ID: 34308516
[TBL] [Abstract][Full Text] [Related]
24. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
25. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
[TBL] [Abstract][Full Text] [Related]
26. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy.
Li Y; Subjeck J; Yang G; Repasky E; Wang XY
Vaccine; 2006 Jun; 24(25):5360-70. PubMed ID: 16714072
[TBL] [Abstract][Full Text] [Related]
27. [Heat-shock protein enhances immunogenicity of E7 oncoprotein of human papillomavirus included in chimeric construction (E7 HPV-HSP70)].
Sveshnikov PG; Solopova ON; Kurbatova EA; Shevchik IuS; Baranovskiĭ PM; Ul'ianov AM; Bokov MN; Kiselev VI
Zh Mikrobiol Epidemiol Immunobiol; 2010; (3):36-9. PubMed ID: 20734716
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu TC; Boux LJ; Mizzen LA; Siegel MI
Cell Stress Chaperones; 2000 Nov; 5(5):401-5. PubMed ID: 11189443
[TBL] [Abstract][Full Text] [Related]
29. Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene.
Gao J; Fan L; Ma W; Xiao H
Microbiol Immunol; 2016 Sep; 60(9):626-33. PubMed ID: 27515281
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
31. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
[TBL] [Abstract][Full Text] [Related]
32. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
[TBL] [Abstract][Full Text] [Related]
33. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
[TBL] [Abstract][Full Text] [Related]
34. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
Peng S; Trimble C; Ji H; He L; Tsai YC; Macaes B; Hung CF; Wu TC
J Biomed Sci; 2005 Oct; 12(5):689-700. PubMed ID: 16200349
[TBL] [Abstract][Full Text] [Related]
35. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
Kim TW; Hung CF; Kim JW; Juang J; Chen PJ; He L; Boyd DA; Wu TC
Hum Gene Ther; 2004 Feb; 15(2):167-77. PubMed ID: 14975189
[TBL] [Abstract][Full Text] [Related]
36. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
[TBL] [Abstract][Full Text] [Related]
37. Antitumor Response to a Codon-Optimized HPV-16 E7/HSP70 Fusion Antigen DNA Vaccine.
Soleimanjahi H; Razavinikoo H; Fotouhi F; Ardebili A
Iran J Immunol; 2017 Sep; 14(3):180-191. PubMed ID: 28919581
[TBL] [Abstract][Full Text] [Related]
38. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.
Lasaro MO; Diniz MO; Reyes-Sandoval A; Ertl HC; Ferreira LC
Microbes Infect; 2005 Dec; 7(15):1541-50. PubMed ID: 16213178
[TBL] [Abstract][Full Text] [Related]
40. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
Sewell DA; Shahabi V; Gunn GR; Pan ZK; Dominiecki ME; Paterson Y
Cancer Res; 2004 Dec; 64(24):8821-5. PubMed ID: 15604239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
